Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026415 · ClinicalTrials.gov registry record · Phase 1
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 73
- Enrollment target
NCT01026415 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 73 participants.
The verdict
NCT01026415, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 73 participants
- Enrollment target
Study Summary
The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).
Interventions
- DRUG brentuximab vedotin
- DRUG midazolam
- DRUG ketoconazole
- DRUG rifampin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2009-12 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026415
The ClinicalTrials.gov registry entry for NCT01026415 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which brentuximab vedotin is the first listed.
NCT01026415 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026415 about?
NCT01026415 is a clinical study titled "Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)". The purpose of this study is to identify brentuximab vedotin drug-drug interactions in patients with CD30-positive cancers and to determine the main route of excretion. The study will also assess blood drug levels in patients with renal or hepatic impairment (special populations).
What is the current status of trial NCT01026415?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 73 participants. The study started on 2009-12. Estimated completion is 2012-05.
What interventions are being tested in trial NCT01026415?
The interventions under investigation include: brentuximab vedotin (DRUG), midazolam (DRUG), ketoconazole (DRUG), rifampin (DRUG).
Who is sponsoring clinical trial NCT01026415?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.